Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if double autologous then allogeneic hematopoietic
cell transplant may offer an improved treatment option for patients with relapsed diffuse
large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional
transplantation regimen.